LINNAEUS BIOSCIENCE, INC.

Biotech · Private

Fungal Cytological Profiling (FCP) platform for high-throughput antifungal drug discovery using quantitative fluorescence microscopy

Grants
$799K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Identification of novel natural products active against MDR pathogens$199,405
Federal grantDepartment of Health and Human Services · Phase I · Identification of macrocyclic molecules with antibacterial activity$300,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Image Based Profiling for Antifungal Discovery$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2755SERODOPA THERAPEUTICS INC——
2756CASTAG BIOSCIENCES, INC.——
2757VAXFORM, LLC——
2758LINNAEUS BIOSCIENCE, INC.——
2759Lassen Therapeutics——
2760ORGANIX, INC.——
2761KOLIBER BIOSCIENCES INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.